Immunotherapy combo aims to beat back recurrent nasopharyngeal cancer

NCT ID NCT05340491

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding an immunotherapy drug called toripalimab to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and who cannot have surgery will be randomly assigned to receive either chemoradiotherapy alone or chemoradiotherapy plus toripalimab. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab (an immunotherapy drug) combined with chemotherapy (gemcitabine and cisplatin) and radiation therapy
What this could lead to: If successful, this combination could improve survival and control of recurrent nasopharyngeal cancer, offering a new treatment option for patients who cannot have surgery.
What could go wrong: This is a phase 3 trial, but results are not yet available. Immunotherapy can cause immune-related side effects, and the added benefit over standard chemoradiotherapy is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, China
Fujian Province Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, China
Guizhou Cancer Hospital
NOT_YET_RECRUITING

Guiyang, China
Jiangxi Cancer Hospital
RECRUITING

Nanchang, China
Peking University Third Hospital
RECRUITING

Beijing, China
Sichuan Cancer Hospital
NOT_YET_RECRUITING

Chengdu, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Guangxi Medical University
RECRUITING

Nanning, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, China
Xijing Hospital
RECRUITING

Xi'an, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, China
Zhongnan Hospital of Wuhan University
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.